ИСТИНА

As it is postulated digoxin (D) has positive effects on CHF symptoms and neutral effects on mortality even in pts with sinus rhythm. The purpose of the present study has been to evaluate the influence of 6 weeks D therapy on status and heart rate variability (HRV) in 30pts with mild CHF and sinus rhythm. (CAD-17 pts, DCMP- 13 pts) been in a double-blinded, randomised (2:1) placebo-controlled clinical trial. D (0.25 mg/day) have been administrated in 19 pts and placebo (Pl) in 11pts. Plus to clinical investigations, registration of maximal oxygen uptake (Vo2peak) during cardiopulmonary exercise test and measurement of norepinephrine level (NE), all pts underwent 2-channel 24-hour ECG Holter monitoring for HR and heart rate variability (SDNN) investigations. The percentage changes that occurred are listed in the table bellow . (*-p<0,05). HR Vo2peak SDNN NE D (n=19) +3,35% +8,18%* +12,98%* -16.7% Pl (n=11) +2,36% +2,38% +4,1% -9.8% Clinical status slightly improved in both, but maximal oxygen uptake significantly improved only in digoxin group. In parallel we found significantly decrease of NE level at rest and concomitant improvement of HRV after digoxin therapy. We conclude that positive effects of digoxin in mild CHF with sinus rhythm partly explained by its neuromodulator activity and improvement oh HRV.